Revium Rx. (RVRC)
OTCMKTS · Delayed Price · Currency is USD
1.500
0.00 (0.00%)
Jan 20, 2026, 4:00 PM EST

Revium Rx. Company Description

Revium Rx. operates as a pre-clinical stage biopharmaceutical company focused on the development of nanoparticle-based therapies in the United States.

The company develops lipid-based platforms for a variety of uses including antimicrobial resistance and solid tumors.

The company specializes in infectious diseases, including antibiotic-resistant infections, solid tumors and vaccination.

The company also develops nano-liposomal particles (NLP) based pharmaceutical candidates. It develops nanoparticles-based formulation of a potent antibiotic; novel adjuvant for cancer therapies: and novel immunization based on liposomal protein-loaded technology.

The company was formerly known as Revium Recovery Inc. and changed its name to Revium Rx. in December 2024.

Revium Rx. was founded in 1997 and is based in Herzliya, Israel.

Revium Rx.
CountryUnited States
Founded1997
IndustryHealth Information Services
SectorHealthcare
Employees7
CEOAmir Avraham

Contact Details

Address:
Azrieli Business Center
Herzliya, Nevada 4672561
Israel
Phone972 1 800 5191687
Websitereviumrx.com

Stock Details

Ticker SymbolRVRC
ExchangeOTCMKTS
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS76151C1009
SIC Code2834

Key Executives

NamePosition
Amir Avraham CPAInterim Chief Executive Officer
Inna MartinPresident, Chief Operating Officer, Secretary and Director
Arie Gordashnikov CPAChief Financial Officer and Treasurer
Dr. Erez KorenChief Technology Officer
Yoram DruckerVice President of Business Development and Director